Under construction – not a live service
Sign in
Taking peoplePhase 2

Tests IMG-007 doses in adults with moderate-to-severe atopic dermatitis

Tests different IMG-007 doses against placebo in adults with atopic dermatitis.

Key facts

Who runs it
Inmagene LLC
Where
Moravska Ostrava A Privoz, Nový Jičín, Pardubice I, Prague, and Prague 10, CzechiaSee the 8 sitesAlso in 8 other countries, 77 sites
Registry title
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Status
Recruiting
Phase
Phase 2
People taking part
405 people, planned
Started
17 Jun 2025
Expected to end
Aug 2028
Type of study
Interventional, 9 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • IMG-007
  • Placebo
Record updated
12 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate-to-severe atopic dermatitis (eczema) who did not respond well to, or could not tolerate, topical treatments.

Age
18 to 74 years
Sex
All sexes can join.
Disease stage
Moderate-to-severe atopic dermatitis: EASI score ≥16, vIGA-AD score ≥3, ≥10% of body surface area affected, and mean peak itch score ≥ 4 in the 7 days before randomization.
Earlier treatment
Must have had an inadequate response or poor tolerance to a stable regimen of one or more topical treatments before screening, or topical treatments are otherwise inadvisable.

Main reasons for not taking part

  • Positive hepatitis B, hepatitis C, or HIV infection
  • Active or latent tuberculosis, or past untreated or inadequately treated TB infection
  • Active infection needing systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals
  • Other active unstable itchy skin conditions that would interfere with assessing AD
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Moderate-to-severe AD
  • Documented history of inadequate response or lack of tolerability to a stable regimen of one or more topical treatment before the Screening visit, or for whom topical treatments are otherwise inadvisable
  • Female participants who are not pregnant or breastfeeding and meet at least one of the following conditions: not of childbearing potential or of childbearing potential and agrees to use a highly effective method of contraception
  • Male participants must agree to use a highly effective method of contraception
  • EASI score ≥16
  • vIGA-AD score ≥3
  • ≥10% body surface area (BSA) of AD involvement
  • Mean peak pruritus numerical rating scale ≥ 4 during 7-days before randomization

Who cannot take part

  • Active infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals
  • Having received any of the specified therapies within the specified timeframe(s) prior to the Baseline visit
  • Positive hepatitis B, hepatitis C, or human immunodeficiency virus infection
  • Evidence of active or latent tuberculosis (TB)
  • History of untreated or inadequately treated TB infection
  • Active unstable pruritic skin conditions in addition to AD that would interfere with the assessment of AD based on the investigator's clinical judgement
  • Other conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 74 years old?

Where in Czechia

Also in 8 other countries, 77 sites

  • CCR Ostrava s.r.o.Moravska Ostrava A Privoz, CzechiaNot yet recruiting
  • Nemocnice AGEL Nový Jičín a.s.Nový Jičín, CzechiaNot yet recruiting
  • Pratia Czech s.r.o.Pardubice I, CzechiaNot yet recruiting
  • Dermatovenerologicka ordinace MUDr. Blanka HavlickovaPrague, CzechiaNot yet recruiting
  • Fakultni nemocnice BulovkaPrague, CzechiaNot yet recruiting
  • Praglandia s.r.o.Prague, CzechiaNot yet recruiting
  • Pratia Czech, s.r.o.Prague, CzechiaNot yet recruiting
  • Clintrial s.r.o.Prague 10, CzechiaNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

The 9 groups in the trial

  • IMG-007 Dose 1Treatment being tested

    Subcutaneous injection as per protocol.

    Treatment: IMG-007

  • IMG-007 Dose 2Treatment being tested

    Subcutaneous injection as per protocol.

    Treatment: IMG-007

  • IMG-007 Dose 3Treatment being tested

    Subcutaneous injection as per protocol.

    Treatment: IMG-007

  • IMG-007 Dose 4Treatment being tested

    Subcutaneous injection as per protocol.

    Treatment: IMG-007

  • IMG-007 Dose 5Treatment being tested

    Subcutaneous injection as per protocol.

    Treatment: IMG-007

  • IMG-007 Dose 6Treatment being tested

    Subcutaneous injection as per protocol.

    Treatment: IMG-007

  • IMG-007 Dose 7Treatment being tested

    Subcutaneous injection as per protocol.

    Treatment: IMG-007

  • Placebo Crossover Dose 1Placebo, for comparison

    Subcutaneous placebo injection as per protocol. At crossover, IMG-007 subcutaneous injection as per protocol.

    Treatment: IMG-007 and Placebo

  • Placebo Crossover Dose 2Placebo, for comparison

    Subcutaneous placebo injection as per protocol. At crossover, IMG-007 subcutaneous injection as per protocol.

    Treatment: IMG-007 and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Plain-language title
Tests IMG-007 doses in adults with moderate-to-severe atopic dermatitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07037901, who can take part
Record updated
12 August 2026